Key highlights

  • Atomo Diagnostics shares were down 10.71% at $0.013 during the 10 November 2026 trading session.
  • Q1 FY27 Revenue reached $1.63 million, up 140% on the prior quarter.
  • FebriDx orders reached $680,000 in the quarter, up 314% year on year.

Atomo Diagnostics Ltd (ASX:AT1) fell 10.71% to $0.013 during the 10 November 2026 trading session. The S&P/ASX 200 was higher by 1.34%, or 121.20 points, at 9,150.90 over the same session. Atomo develops point-of-care diagnostic tests, including its FebriDx product. Its latest update was an Appendix 4C and quarterly activities report for the three months to 30 September 2026, known as Q1 FY27, released on 29 October 2026.

Revenue and cash position

Atomo reported revenue of $1.63 million for the quarter, an increase of 140% on the prior quarter. FebriDx orders reached $680,000 in the quarter, up 314% year on year.

Cash receipts totalled $2.51 million, comprising $2.40 million from customers and $84,000 from the CRC-P grant for its Active Syphilis program. Cash on hand at quarter end was $2.67 million.

Pipeline and partnerships

Atomo signed an agreement with Innovation Scientific to develop a Generation 4 HIV product, adding to its proprietary pipeline. It also announced a Partnership with Upfront Diagnostics for a rapid brain disease test.

The Active Syphilis test completed technology transfer to manufacturing, and preparations are under way for Clinical Trials to begin in the new calendar year.

Sector context

Point-of-care diagnostics companies are often judged on their commercial sales and on the progress of clinical and regulatory programs. Investors compare revenue growth against cash burn and the timing of new product launches. At about one cent, Atomo shares are priced in Penny Stock territory, and the broader market was higher during the session.

Risks

Clinical trials for the Active Syphilis test are planned for the new calendar year and may face delays or require further work. Partnerships and new product programs carry development and commercialisation risks.

Revenue from a small number of products can change quarter to quarter, and cash on hand will need to fund ongoing development.

What to watch ahead

Investors will be watching for the start of clinical trials for the Active Syphilis test, progress on the Generation 4 HIV and rapid brain disease programs, and the December quarter Cash Flow report.

Final Word

Atomo's Trading session decline came after a quarter that showed higher revenue and order growth alongside pipeline progress. The start of the planned clinical trials will be an important marker for the company's next phase.